Format

Send to

Choose Destination
Mult Scler. 2013 Feb;19(2):241-4. doi: 10.1177/1352458512444915. Epub 2012 Apr 5.

Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.

Author information

1
Department of Clinical Neurosciences, University of Cambridge, Level 6 A Block, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK. tb253@medschl.cam.ac.uk

Abstract

The magnetization transfer ratio reflects the integrity of tissue structure, including myelination and axonal density. Mean magnetization transfer ratio fell in 18 untreated patients with multiple sclerosis both in normal appearing grey (-0.25 pu/year, p < 0.001) and white matter (-0.12 pu/year, p = 0.004). Conversely, mean magnetization transfer ratio was stable in 20 alemtuzumab-treated patients (grey matter: -0.01 pu/year, p = 0.87; white matter: -0.02 pu/year, p = 0.51). The gradient difference in grey matter was 0.25 pu/year (p < 0.001) after age-adjustment. These data suggest that in multiple sclerosis alemtuzumab protects against tissue damage in normal-appearing grey matter, perhaps by preventing new lesion formation.

PMID:
22492133
DOI:
10.1177/1352458512444915
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center